Beta Drugs Limited
Track this name
Business & moat
Business Snapshot
Moat Analysis
Performance & outlook
Quarterly Score
Growth Prospects
FY27 base-case growth 20-25%
Management & drivers
Guidance Tracker
Key Variables
Capacity utilization — Capacity utilization has remained moderate across oral and injectable lines, with Lyo running near full. The headroom to generate INR700-800 Cr revenue without major capex indicates significant operating leverage, but also suggests that near-term growth is not